Terms: = Ovarian cancer AND PLAG1, ENSG00000181690, 5324
5 results:
1. TEAD4 predicts poor prognosis and transcriptionally targets PLAGL2 in serous ovarian cancer.
Tong X; Liu YS; Tong R; Tang WW; Li XM; Wang CY; Wang YP
Hum Cell; 2023 Jul; 36(4):1535-1547. PubMed ID: 37145265
[TBL] [Abstract] [Full Text] [Related]
2. Stratifying the risk of ovarian cancer incidence by histologic subtypes in the Korean Epithelial ovarian cancer Study (Ko-EVE).
Sung S; Hong Y; Kim BG; Choi JY; Kim JW; Park SY; Kim JH; Kim YM; Lee JM; Kim TJ; Park SK
Cancer Med; 2023 Apr; 12(7):8742-8753. PubMed ID: 36789760
[TBL] [Abstract] [Full Text] [Related]
3. plag1 silencing promotes cell chemosensitivity in ovarian cancer via the IGF2 signaling pathway.
Huang W; Li BR; Feng H
Int J Mol Med; 2020 Mar; 45(3):703-714. PubMed ID: 31922228
[TBL] [Abstract] [Full Text] [Related]
4. Uterine mesenchymal tumours: recent advances.
Momeni-Boroujeni A; Chiang S
Histopathology; 2020 Jan; 76(1):64-75. PubMed ID: 31846533
[TBL] [Abstract] [Full Text] [Related]
5. Hospital costs associated with adverse events in gynecological oncology.
Kondalsamy-Chennakesavan S; Gordon LG; Sanday K; Bouman C; De Jong S; Nicklin J; Land R; Obermair A
Gynecol Oncol; 2011 Apr; 121(1):70-5. PubMed ID: 21168196
[TBL] [Abstract] [Full Text] [Related]
